← All trials
NCT05099029
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 27, 2018
- Primary completion
- Jun 30, 2022
- Completion date
- May 21, 2024
- First posted
- Oct 29, 2021
- Last posted
- Nov 17, 2021
- Enrollment
- 3982
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Enimmune CorporationLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.